Patients With Sj ögren Syndrome Fall Into Distinct Subgroups Patients With Sj ögren Syndrome Fall Into Distinct Subgroups
Those with high systemic disease activity but low symptom burden fared worse over time.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 20, 2024 Category: Allergy & Immunology Tags: Rheumatology Source Type: news
Mayo Clinic Minute: Spring pollen and allergy tips
If you are one of the millions of people who suffer pollen and allergies, you don't need a calendar to tell you that spring has started. Sometimes called hay fever, allergic rhinitis can sometimes be confused with a cold. So, what's happening and what can you do? While hay fever alone may not be life threatening, it can be uncomfortable, says Dr. Arveen Bhasin, a Mayo Clinic allergy and immunology expert. She offers these tips for relief from spring… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 20, 2024 Category: Databases & Libraries Source Type: news
Roflumilast Cream Quickly Improved AD in Children, Ages 2-5 Roflumilast Cream Quickly Improved AD in Children, Ages 2-5
Among patients treated with roflumilast cream, 0.05%, 25.4% reached the primary endpoint of " clear " or " almost clear " plus a two-grade improvement from baseline at week 4.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 19, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Children with allergies 'put at risk by schools'
The family of a five-year-old who died after collapsing at school is calling for more legislation. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - March 19, 2024 Category: Consumer Health News Source Type: news
AstraZeneca to Cap Out-of-pocket Inhaler Costs in US, Following Rival Boehringer's Move AstraZeneca to Cap Out-of-pocket Inhaler Costs in US, Following Rival Boehringer's Move
Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from June, following a...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 19, 2024 Category: Allergy & Immunology Tags: Pulmonary Medicine Source Type: news
First Treatment Approved for Chronic Rhinosinusitis Without Nasal Polyps
(MedPage Today) -- The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on Friday.
The drug-device combination... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 19, 2024 Category: Allergy & Immunology Source Type: news
AstraZeneca Follows Rival Boehringer in Capping Out-of-pocket Costs for Inhalers AstraZeneca Follows Rival Boehringer in Capping Out-of-pocket Costs for Inhalers
Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 18, 2024 Category: Allergy & Immunology Tags: Pulmonary Medicine Source Type: news
'I'm a hay fever expert - this trick will stop you from becoming a snotty mess in spring'
There are six simple steps you can take to stay on top of allergy season, according to an expert. (Source: Daily Express - Health)
Source: Daily Express - Health - March 18, 2024 Category: Consumer Health News Source Type: news
Are Your Patients' Allergies Worsening? Climate Change May Be at Play
(MedPage Today) -- 'Tis the season of warmer temperatures, blue skies, and the slow shedding of layers. While I, like many others, welcome this warmer weather, I am also weary of how unseasonably warm the winter has been. This past January was... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 17, 2024 Category: Pediatrics Source Type: news
Walmart nuts RECALLED in 30 US states over potentially fatal allergies
An in-store brand of Walmart's 'honey roasted' cashews have been recalled in 30 US states and from their online retail site due to the risk of potentially fatal allergies. The US Food and Drug Administration (FDA) issued the notice Wednesday, warning consumers that 'a limited amount' of 8.25 oz…#walmart #fda #vermont #johnbsanfilipposon #squirrelbrand #southernstylenuts #jbss #upc #annalsofallergy #mayoclinic (Source: Reuters: Health)
Source: Reuters: Health - March 16, 2024 Category: Consumer Health News Source Type: news
‘Lab-leak’ proponents at Rutgers accused of defaming and intimidating COVID-19 origin researchers
Fraudsters. Liars. Perjurers. Felons. Grifters. Stooges. Imbeciles. Murderers. When it comes to describing scientists whose peer-reviewed studies suggest the COVID-19 virus made a natural jump from animals to humans, molecular biologist Richard Ebright and microbiologist Bryce Nickels have used some very harsh language. On X (formerly Twitter), where the two scientists from Rutgers University are a constant presence, they have even compared fellow researchers to Nazi war criminals and the genocidal Cambodian dictator Pol Pot.
But now, their targets have had enough. A dozen scientists filed a
formal complaint
...
Source: ScienceNOW - March 15, 2024 Category: Science Source Type: news
Xhance Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 15, 2024 Category: Drugs & Pharmacology Source Type: news
Prurigo Nodularis: Nemolizumab Efficacy Persists at 52 Weeks Prurigo Nodularis: Nemolizumab Efficacy Persists at 52 Weeks
The encouraging long-term efficacy and safety associated with nemolizumab (IL-31 inhibitor) in prurigo nodularis was supported by a second set of data showing long-term benefit in atopic dermatitis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 15, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Most Baby Cleansers Are Not'Allergen-Free,' Study Finds Most Baby Cleansers Are Not'Allergen-Free,' Study Finds
A recent study demonstrated that 94% of top-selling baby cleansers contain allergens, despite having hypoallergenic claims.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 15, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Food Allergy Highlights From AAAAI 2024 Food Allergy Highlights From AAAAI 2024
Food allergy highlights from AAAAI 2024 include strong results for omalizumab against multiple food allergens and comparable efficacy for intranasal epinephrine vs injectable anaphylaxis therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2024 Category: Consumer Health News Tags: None ReCAP Source Type: news
